Microbix signs agreement to develop adenovirus vectors for GE Healthcare’s sub-cellular analysis system

Toronto, ON – July 26, 2004 – Microbix Biosystems says it has signed a contract with GE Healthcare (a combination of the former Amersham and GE Medical Systems) aimed at facilitating faster and more efficient drug development.

Under the terms of the contract, Microbix says it will develop a portfolio of recombinant adenoviruses for use with GE Healthcare’s sub-cellular imaging systems, the IN Cell Analyzer 3000 and IN Cell Analyzer 1000. A range of ready-to-use assays will be developed to enable researchers to study key cellular events in real-time and in a cell line of choice. This will enable more biologically relevant results to be obtained, and so advance the drug discovery process.

“This contract is the latest in the continuing successful commercialization of our core technology platforms, and confirms that we remain market leader in the area of adenovirus technologies,” said William J Gastle, president and CEO of Microbix.